August 16, 2018

MIPS INTERIM REPORT JANUARY – JUNE 2018

7:30 am / August 16, 2018 APR – JUN Net sales increased by 52% to SEK 55.6m (36.6). Adjusted for currency exchange rate effects the increase was 53% Operating profit...
Read more
August 16, 2018

Nexstim Plc Half-Yearly Report 1 January – 30 June 2018 (unaudited)

Company announcement, Helsinki, 16 August 2018 at 9:00 am Highlights, January – June 2018 Nexstim delivered its first Navigated Brain Therapy (NBT®) system in the US for t...
Read more
August 16, 2018

BONESUPPORT – CERAMENT® G Approved by Health Canada

Lund, Sweden, 18:00 CET, 16 August 2018 - BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that its antibiotic-eluting product ...
Read more
August 15, 2018

Targovax ASA: Invitation to second quarter and first half year 2018 results presentation Thursday 23 August

Oslo, Norway, 15 August 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, will announce its...
Read more
August 15, 2018

Strongbridge Biopharma plc Announces Termination of Public Offering of Ordinary Shares

DUBLIN, Ireland and TREVOSE, Pa., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it has terminated the pu...
Read more
August 14, 2018

Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares

DUBLIN, Ireland and TREVOSE, Pa., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it intends to offer and ...
Read more
August 10, 2018

MIPS: Invitation to the presentation of the results for the period January – June 2018

Fri, Aug 10, 2018 14:00 CETMIPS releases its Interim report for the period January to June on August 16 at 7:30 am (CET). Johan Thiel, President and CEO and Max Strandwi...
Read more
August 9, 2018

Notice of Nexstim Plc’s Half-Yearly Report H1 2018

Company announcement, Helsinki, 9 August 2018 at 9:00 AM Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or the "Company"), the targeted neuromodulation company developing and mar...
Read more
August 9, 2018

Anders Martin-Löf has been appointed as the new CFO of Oncopeptides

Stockholm – August 9, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Anders Martin-Löf, has been appointed as the new CFO of Oncopeptides and will jo...
Read more
August 8, 2018

Strongbridge Biopharma plc Announces Positive Top-Line Results from the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome

~ SONICS Study Met Primary Endpoint with RECORLEV Demonstrating a Statistically Significant Normalization Rate of Urinary Free Cortisol at Six Months ~ ~ Key Secondary Endpoints ...
Read more